Yan Leyfman: What happens after patients stop taking GLP-1 receptor agonists
Yan Leyfman, Co-founder and Executive Director of MedNews Week, shared an article by Sara Berg, et al. on LinkedIn:
“A systematic review and meta-analysis explores an often-overlooked question:
What happens after patients stop taking GLP-1 receptor agonists (GLP-1RAs) like semaglutide, tirzepatide, or liraglutide?
After screening nearly 500 studies, we included 8 randomized controlled trials (2,372 participants, all with BMI ≥27). Results showed that weight regain was proportional to the original weight lost once the medication was discontinued:
Liraglutide: +2.2 kg regained
Semaglutide/Tirzepatide: +9.7 kg regained
(all with statistically significant confidence intervals)
Bottom line: Discontinuing GLP-1RA treatment often leads to significant weight regain—an important point for both patients and providers to consider when planning long-term management.”
Authors: Sara Berg, Hannah Stickle, Suzanne J. Rose, Eric C. Nemec.
More posts featuring Yan Leyfman.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023